MedTrace Logo

Study of IMC-1121B in Patients With Tumors That Have Not Responded to Therapy

NCT00793975 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2013-08-19

No results posted yet for this study

Summary

The purpose of this study is to determine if IMC-1121B is safe for patients, and to determine the best dose of IMC-1121B to give to patients.

Conditions

Interventions

BIOLOGICAL

IMC-1121B

Cohort 1 2 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period.

BIOLOGICAL

1121B

Cohort 2 4 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period.

BIOLOGICAL

1121B

Cohort 3 6 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period.

BIOLOGICAL

1121B

Cohort 4 8 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period.

BIOLOGICAL

1121B

Cohort 5 10 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period.

BIOLOGICAL

1121B

Cohort 6 13 mg/kg once a week for 4 weeks, followed by a 2-week observation period.

BIOLOGICAL

1121B

Cohort 7 16 mg/kg once a week for 4 weeks, followed by a 2-week observation period.

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00793975 on ClinicalTrials.gov